overview of engot-ov16/nova of niraparib in ovarian cancer and why the results were not surprising
Published 7 years ago • 429 plays • Length 3:10Download video MP4
Download video MP3
Similar videos
-
9:25
results from the engot-ov16/nova trial: efficacy and safety of niraparib in ovarian cancer
-
2:55
results of engot-ov16/nova phase iii trial of niraparib in platinum-sensitive ovarian cancer
-
2:26
trial design of engot-ov16/nova phase iii trial of niraparib in platinum-sensitive ovarian cancer
-
1:50
niraparib as maintenance for platinum-sensitive ovarian cancer - results from engot-ov16/nova trial
-
1:14
next steps for niraparib for ovarian cancer following on from the engot-ov16/nova trial
-
1:13
comparison of trials of niraparib, olaparib and rucaparib in ovarian cancer
-
5:13
treating ovarian cancer with niraparib: the nova trial
-
2:39
nova phase iii trial of niraparib in platinum-sensitive ovarian cancer patients
-
3:11
the avanova study: niraparib and bevacizumab for ovarian cancer
-
1:47
dr. matulonis on the nova trial of niraparib maintenance therapy in ovarian cancer
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
3:23
niraparib significantly improves outcomes for ovarian cancer patients
-
2:25
results of niraparib/bevacizumab combo in platinum-sensitive recurrent ovarian cancer
-
6:31
prima: frontline niraparib maintenance therapy in ovarian cancer
-
2:35
clinical use of niraparib in ovarian cancer
-
0:59
the evolution of parp inhibitors in ovarian cancer
-
1:35
dr. mirza on the phase iii nova trial in ovarian cancer
-
1:24
innovations in ovarian cancer treatment: parp inhibitors
-
5:34
differences among parp inhibitors in ovarian cancer